Trial Profile
Intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer: A Phase II Single-arm Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 06 Jul 2017 New trial record